Activating mutations of genes in the receptor tyrosine kinase RAS-BRAF (RTK/RAS-BRAF) signal transduction pathway are common in myelodysplasia (MDS) and acute myeloid leukemia (AML) [1] [2] [3] [4] and in the therapy-related subsets of these diseases (t-MDS/t-AML). 5 Recently, a specific activating mutation of the JAK2 tyrosine kinase was detected in 154/201 cases of polycythemia vera (77%), in 21/44 cases of idiopatic myelofibrosis (48%) and in 50/144 cases of essential thrombocythemia (35%). 6, 7 The JAK2V617F mutation was subsequently observed only sporadically in 3/119 cases of chronic myelomonocytic leukemia, including a case with a history of B cell lymphoma, and in 5/101 cases of MDS including four patients with a normal karyotype. 8 In our systematic search for genetic abnormalities in t-MDS and t-AML and their association to clinical parameters and cytogenetic characteristics, we examined 140 unselected patients with t-MDS or t-AML previously examined for mutations in the RTK/RAS-BRAF pathway 5 for the JAK2V617F mutation. PCR amplification and direct sequencing of JAK2 exon 12 was performed as previously reported 5 using primers described elsewhere. Direct DNA sequence analysis of JAK2 exon 12. At the top, a wild-type sequence from a normal control is shown for comparison. The middle sequence shows equal fluorescence intensities of the mutated and the wild-type alleles in patient 43, whereas at the bottom the sequence of the wild-type allele of patient 179 is only faintly visible.
Letters to the Editor JAK2V617F mutation (Table 1) . JAK2 mutation was not observed among 51 patients presenting as overt t-AML. In case 43, equal fluorescence intensities of the mutated and of the wild-type alleles were observed, suggesting heterozygousity or alternatively a mixture of clonal leukemic cells with homozygous mutation of JAK2 and normal nonclonal hematopoietic precursor cells with wild-type JAK2 in the sample (Figure 1) . In case 179, however the wild-type allele was only faintly visible, suggesting loss of heterozygosity of the JAK2 gene ( Figure 1 ).
Both patients with JAK2 mutations had previously been treated with high voltage radiotherapy, and patient 43 had in addition received combination chemotherapy including cyclophosphamide for 2 years (Table 1) . After a latent period of 77 and 72 months, respectively, the two patients developed a myeloid disorder previously classified as atypic t-MDS with splenomegaly and a normal karyotype.
Patient 43 presented with normal Hb, WBC: 18.7 Â 10 9 /l and thrombocytes: 43 Â 10 9 /l. Differential count was normal with mature granulocytes. Bone marrow was hyperplastic and fibrotic with abnormal megakaryocytes, no blasts or promyelocytes but 8% myelocytes. The spleen was moderately enlarged but splenomegaly progressed by time and transcobalamin I was increased: 1.95 mg/l (normalo0.3). Splenectomy was carried out without improvement of hematologic parameters. The performance detoriated without development of t-AML, and death was due to complicating pneumonia.
Patient 179 presented with anemia Hb: 4.7 mmol/l and WBC: 254 Â 10 9 /l mainly mature granulocytes, and platelet count was normal. Bone marrow was hyperplastic and fibrotic with leukoerythroblastosis, myeloblasts 2%, promyelocytes 5% and myelocytes 7%. There was severe splenomegali and hepatomegali. The patient was treated with hydroxyurea for 2 months without any response and expired. At autopsy, the spleen, liver, lymphnodes and kidney were enlarged with extensive myeloid metaplasia.
t-MDS or t-AML with a normal karyotype comprises a less frequent but interesting group of patients previously classified in a specific genetic pathway. 9 In our unselected series of 140 patients studied genetically, only 24 presented a normal karyotype including nine of 89 patients presenting as t-MDS and 15 of 51 presenting as overt t-AML. In a previous study, RAS mutations were observed in three of the only nine patients with t-MDS and a normal karyotype (cases 46, 132 and 136), 5 and we have now identified JAK2 mutations in an additional two patients.
Patients with t-MDS or t-AML and normal or atypic cytogenetics are often uncharacteristic cases as far as clinical data and the molecular biology are concerned. They may develop with an extremely short or long latent period as observed in case 136 with N-RAS mutation, and after radiotherapy only as case no. 179 in the present study. Very few patients present myeloproliferative features with splenomegaly. Such a pattern was only observed in the two cases with JAK2 mutations reported here. As far as the aetiology of such cases is concerned, they may represent spontaneous cases of MDS or AML de novo, or previous radiotherapy could play a role. Table 1 Clinical and cytogenetic characteristics of two patients with atypic t-MDS and JAK2V617F activating mutation VCR, vincristine; Pred, prednisone; Stn, streptonigrin; COP, cyclophosphamide+vincristine+prednisone.
